NVCT News and Press, Nuvectis Pharma Inc. From 08/05/25

NXP900 becomes the lead drug candidate after successfully completing the Phase 1a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers; initiation of Phase 1b program is imminent Strengthened cash position following a July At-The...

SOPHiA GENETICS SA (SOPH) is expected to report for Q2 2025 Investors Title Company (ITIC) is expected to report for Q2 2025 Safehold Inc. (SAFE) is expected to report $0.39 for Q2 2025 First Guaranty Bancshares Inc. (FGBI) is expected to report $-0.2 for Q2 2025 United Fire Group...

Nuvectis Pharma Inc. (NVCT) is expected to report $-0.25 for Q2 2025

Available data from 13 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer treated with 75 mg/day in the NXP800 Phase 1b study includes 2 partial responses and 3 stable diseases; thrombocytopenia successfully managed with intermittent dosing schedule; observed clinical acti...

2025-07-22 12:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Drug-drug interaction (“DDI”) clinical studies help identify the potential for side effects, or in some cases, reduced therapeutic efficacy, that may be caused by interactions between different drugs. The market leading epidermal growth factor receptor (“EGFR”) and...

2025-07-01 14:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2025-06-18 12:29:51 ET Topline Summary and Update Read the full article on Seeking Alpha For further details see: Nuvectis Pharma: Still Interesting, But Still Too Risky To Jump In

Fort Lee, NJ, May 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, tod...

2025-05-08 08:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...